Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Deregulation of HLA-I in cancer and its central importance for immunotherapy.

Journal article

Hazini A. et al, (2021), J Immunother Cancer, 9

Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus.

Journal article

Hill C. et al, (2021), Mol Ther Oncolytics, 21, 47 - 61

Tackling HLA Deficiencies Head on with Oncolytic Viruses.

Journal article

Fisher K. et al, (2021), Cancers (Basel), 13

NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer.

Journal article

Leung EYL. et al, (2020), Mol Ther Oncolytics, 16, 289 - 301

The role of cancer metabolism in defining the success of oncolytic viro-immunotherapy

Journal article

Dyer A. et al, (2020), Cytokine and Growth Factor Reviews

Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples.

Journal article

Scott EM. et al, (2019), J Immunother Cancer, 7

Targeting T-cells to human cancer associated fibroblasts using an oncolytic virus expressing a FAP-specific T-cell engager

Conference paper


Making Oncolytic Virotherapy a Clinical Reality: The European Contribution.

Journal article

Duffy MR. et al, (2017), Hum Gene Ther, 28, 1033 - 1046

Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.

Journal article

Freedman JD. et al, (2017), EMBO Mol Med, 9, 1067 - 1087

Load More